Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Titan Pharmaceuticals (TTNP)

Add TTNP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Rentier, Truth4Once
Search This Board:
Last Post: 8/28/2014 12:43:45 AM - Followers: 156 - Board type: Free - Posts Today: 2



Probuphine®-This study is enrolling participants by invitation only.

Click For Link To

*As of August 14, 2014 - Approximately 20% enrolled.


Braeburn Pharmaceuticals Identifier:
Information provided by (Responsible Party):
First received: July 1, 2014
Last updated: July 8, 2014
Last verified: July 2014
Braeburn Pharmaceuticals

Probuphine Graphic




Continuous Drug Delivery Technology


The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.


Fanapt® (iloperidone)


Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis Pharma AG (“Novartis”) in the U.S. Titan is entitled to a royalty of 8-10% of net sales of Fanapt under a sublicense agreement with Novartis that is based on a U.S. patent which expires in October 2016 (does not include a possible six-month pediatric extension).

Titan has entered into several agreements with Deerfield Management LP (“Deerfield”), which entitle Deerfield to most of the future royalty revenues related to Fanapt in exchange for cash and debt considerations, the proceeds of which have been used to advance the development of Probuphine and for general corporate purposes. Titan has retained a portion of the royalty revenue from net sales of Fanapt in excess of specified annual threshold levels; however, based on sales levels to date, it is unlikely that Titan will retain any revenue from Fanapt in the next several years, if ever. Titan does not incur any ongoing expenses associated with this product.

Company Overview

Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents.


Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction. The confirmatory Phase 3 study is currently being conducted at 20 sites in the U.S., and the results of this study are expected in Q2, 2011. Additional information on the Probuphine program is available in the PRODUCTS section of this website.


The Company's common stock is traded on the OTC Bulletin Board Markets ([TTNP.OB] quotations system. For further information please contact


Management Team

Sunil Bhonsle, M.B.A.

Executive Vice President and Chief Development Officer

Katherine L. Beebe, Ph.D.

Executive Chairman

Marc Rubin, M.D.


Board of Directors



Strategic Alliances

In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.


Product Overview

The investigational products are at various stages of development as listed below.

Titan Pharmaceuticals Products

In addition to the potential royalty revenues from iloperidone, Titan is currently focused on adding value to the company from these assets, particularly Probuphine. Additional information on Probuphine and other programs are available in the next sections. If you are interested in learning more, please contact Sunil Bhonsle, President, at


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TTNP News: Quarterly Report (10-q) 08/13/2014 02:35:21 PM
TTNP News: Current Report Filing (8-k) 07/21/2014 05:13:36 PM
TTNP News: Current Report Filing (8-k) 06/09/2014 05:11:54 PM
TTNP News: Titan Pharmaceuticals Receives Notice of Allowance for Patent of Implantable Polymeric Device for Sustained Release of Dopami... 06/09/2014 07:00:00 AM
TTNP News: Statement of Ownership (sc 13g) 05/21/2014 03:22:30 PM
#3434  Sticky Note Titan Pharmaceuticals Announces Second Quarter 2014 Financial Results Truth4Once 08/14/14 03:41:33 AM
#3483   Turks Love your posts. This isn't a English exam. bluejacket6 08/28/14 12:43:45 AM
#3482   Turks Love your posts. This isn't a English exam. bluejacket6 08/28/14 12:42:49 AM
#3481   I honestly don't know the answer...when they ran matthewverymuch 08/27/14 09:30:46 PM
#3480   WTH?! How can this "Come on guys RELAX,everything seems Rentier 08/27/14 07:49:32 PM
#3479   Come on guys RELAX,everything seems to be going turks 08/27/14 11:24:03 AM
#3478   If you notice,my tone was the same prior Truth4Once 08/26/14 06:02:42 PM
#3477   Since the CC what more information are you bluejacket6 08/26/14 05:35:06 PM
#3476   it seems your disappointed that TTNP handed over Truth4Once 08/26/14 05:30:23 PM
#3475   Somehow Truth it seems your disappointed that TTNP bluejacket6 08/26/14 05:19:43 PM
#3474   .815 is my average.. i probably don't have matthewverymuch 08/26/14 01:08:18 PM
#3473   I thought you dollar cost averaged down.... Truth4Once 08/26/14 01:04:21 PM
#3472   Braeburns average is .96 i think..i would kill matthewverymuch 08/26/14 01:00:05 PM
#3471   why is this year so different? Truth4Once 08/26/14 12:58:43 PM
#3470   There hasn't been volume anywhere on the OTC hyrpowr 08/26/14 12:54:47 PM
#3469   Just to satisfy my curiousity about the summer matthewverymuch 08/26/14 12:40:09 PM
#3468   What are they doing? Truth4Once 08/26/14 11:52:39 AM
#3467   I know braeburn is a private co, but matthewverymuch 08/26/14 11:03:51 AM
#3466   Hello mvm, Truth4Once 08/26/14 10:51:14 AM
#3465   Looks like the 50's are a given really matthewverymuch 08/26/14 10:21:38 AM
#3464   hope they follow through. Truth4Once 08/25/14 03:54:12 PM
#3463   Activism is always good. Higgins asked the question bluejacket6 08/25/14 03:45:04 PM
#3462   I am a big proponent of management keeping Truth4Once 08/25/14 03:39:31 PM
#3461   I am a big proponent of management keeping bluejacket6 08/22/14 03:48:12 PM
#3460   Setup an adequate Investors Relations channel.... Truth4Once 08/22/14 01:06:03 PM
#3459   he and his group are pushing them to Truth4Once 08/22/14 01:02:38 PM
#3458   What would you like to see them do? matthewverymuch 08/22/14 01:01:51 PM
#3457   Higgins relayed to me that mgmt is going matthewverymuch 08/22/14 12:52:46 PM
#3456   I'd be more inclined to say they are Truth4Once 08/22/14 12:51:48 PM
#3455   I'd be more inclined to say they are bluejacket6 08/22/14 12:34:39 PM
#3453   Titan is just trying to conserve money and Truth4Once 08/21/14 08:19:59 PM
#3452   Hey blue really don't think you'll have to Rentier 08/21/14 06:32:39 PM
#3451   .67 is showing some significant interest matthewverymuch 08/21/14 02:10:25 PM
#3450   Actually Turks we should all be happy with bluejacket6 08/21/14 12:41:46 PM
#3449   August really sucks, trading horrible, the weather is turks 08/20/14 11:08:21 PM
#3448   Though it would be nice, trading at a matthewverymuch 08/20/14 09:10:35 PM
#3447   Hey blue really don't think you'll have to turks 08/20/14 12:35:39 PM
#3446   You're already up! matthewverymuch 08/20/14 12:01:30 PM
#3445   Both you and Matt spot on no problem bluejacket6 08/20/14 11:28:05 AM
#3444   Lol matt, Don't think he will have a turks 08/18/14 10:36:21 PM
#3443   Somehow i don't think you'll have a problem matthewverymuch 08/18/14 04:46:39 PM
#3442   Need this puppy to stay at these levels bluejacket6 08/18/14 03:48:15 PM
#3441   THANKS MATT,i got it also,great read. turks 08/15/14 04:17:21 PM
#3440   I have his amended report..came out today...if you matthewverymuch 08/15/14 03:39:14 PM
#3439   just got in, and read the transprit thanks turks 08/15/14 03:28:47 PM
#3438   Titan Pharmaceuticals Stock Rating Reaffirmed by Zacks (TTNP) Truth4Once 08/15/14 07:54:35 AM
#3437   Titan Pharmaceuticals (TTNP) Q2 2014 Results - Earnings matthewverymuch 08/14/14 05:37:40 PM
#3436   35-40 patients enrolled (~20%)..2/3 sites activated. Chugging along..conferences matthewverymuch 08/14/14 02:04:22 PM
#3435   Conference call 45 minutes away. Hope to hear bluejacket6 08/14/14 12:16:40 PM
#3434   Titan Pharmaceuticals Announces Second Quarter 2014 Financial Results Truth4Once 08/14/14 03:41:33 AM
#3433   Liked what I read in the quarterly. No bluejacket6 08/13/14 10:26:52 AM